Heghine Khachatryan: Addressing Critical Gaps in Cancer-Associated VTE
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from RPTH Journal on LinkedIn, adding:
”Cancer-associated VTE: an old problem, still unresolved
Despite decades of research, cancer-associated venous thromboembolism (VTE) remains a major cause of morbidity and mortality.
This timely editorial in Research and Practice in Thrombosis and Haemostasis highlights critical gaps—from real-time epidemiologic data to optimal thromboprophylaxis and bleeding risk stratification—and points toward future, cancer-specific solutions.
A strong reminder that prevention, individualized risk assessment, and innovation in anticoagulation must remain a global priority in oncology and hematology.
Editorial by Alok Khorana
Research and Practice in Thrombosis and Haemostasis”
Quoting RPTH Journal‘s post:
”Cancer-associated VTE: an old problem, still unresolved
RPTH Journal Editorial by Alok Khorana
As highlighted by Maiocco et al. in RPTH Journal, it remains puzzling that VTE, a complication of cancer known since the 19th century, continues to heavily burden modern oncology care.
- Cancer patients face a 9- to 20-fold higher risk of VTE, even with contemporary therapies
- In a nationwide US inpatient analysis, 8.1% of cancer-related hospitalizations were complicated by VTE
- VTE remains strongly associated with higher mortality, longer hospital stays, and higher costs
- Despite decades of awareness, robust evidence for inpatient thromboprophylaxis in cancer patients is still lacking
Read the editorial here
Read the study by Giuseppe Maiocco et al here”
Title: The public health impact of cancer-associated venous thromboembolism: looking to the future
Authors: Alok Khorana
Read the Full Editorial on RPTH Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 3, 2026, 21:25Matteo Foschi: Happy to Join the Italian Stroke Association Summer School
-
Jul 3, 2026, 20:39Maha Othman: Excited to Present on PPH for The Lancet Haematology Commission on Global Female Health
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics
-
Jul 3, 2026, 18:24Alexandros Rampotas: Targeting Mutant CALR With Precision CAR-T Therapy
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare